SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:oru-37789"
 

Search: onr:"swepub:oai:DiVA.org:oru-37789" > Autologous haematop...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Burman, JoachimUppsala universitet,Neurologi,Uppsala University, Sweden; University of Uppsala Hospital, Sweden (author)

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis : the Swedish experience

  • Article/chapterEnglish2014

Publisher, publication year, extent ...

  • 2014-02-19
  • London, United Kingdom :BMJ Publishing Group Ltd,2014
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-37789
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-37789URI
  • https://doi.org/10.1136/jnnp-2013-307207DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-223632URI
  • https://lup.lub.lu.se/record/4871317URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-112836URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:130106714URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-97239URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic and sustained follow-up of treated patients constitute important information about safety and efficacy. In this observational study, we describe the characteristics and outcome of the Swedish patients treated with HSCT for MS.Methods: Neurologists from the major hospitals in Sweden filled out a follow-up form with prospectively collected data. Fifty-two patients were identified in total; 48 were included in the study and evaluated for safety and side effects; 41 patients had at least 1 year of follow-up and were further analysed for clinical and radiological outcome. In this cohort, 34 patients (83%) had relapsing-remitting MS, and mean follow-up time was 47 months.Results: At 5 years, relapse-free survival was 87%; MRI event-free survival 85%; expanded disability status scale (EDSS) score progression-free survival 77%; and disease-free survival (no relapses, no new MRI lesions and no EDSS progression) 68%. Presence of gadolinium-enhancing lesions prior to HSCT was associated with a favourable outcome (disease-free survival 79% vs 46%, p=0.028). There was no mortality. The most common long-term side effects were herpes zoster reactivation (15%) and thyroid disease (8.4%).Conclusions: HSCT is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centres.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Iacobaeus, EllenKarolinska Institutet (author)
  • Svenningsson, AndersUmeå universitet,Klinisk neurovetenskap(Swepub:umu)ansv0041 (author)
  • Lycke, JanDepartment of Neurology, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden (author)
  • Gunnarsson, Martin,1973-Örebro universitet,Institutionen för läkarutbildning,Department of Neurology, Örebro University Hospital, Örebro, Sweden(Swepub:oru)mign (author)
  • Nilsson, PetraLund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital Lund, Sweden(Swepub:lu)neur-pn8 (author)
  • Vrethem, MagnusÖstergötlands Läns Landsting,Linköpings universitet,Avdelningen för neurovetenskap,Hälsouniversitetet,Neurologiska kliniken(Swepub:liu)magvr07 (author)
  • Fredrikson, StenKarolinska Institutet (author)
  • Martin, ClaesKarolinska Institutet (author)
  • Sandstedt, AnnaLinköpings universitet,Institutionen för samhälls- och välfärdsstudier,Hälsouniversitetet(Swepub:liu)annsa08 (author)
  • Uggla, Bertil,1962-Örebro universitet,Institutionen för läkarutbildning,Region Örebro län,Division of Hematology, Department of Medicine, Örebro University Hospital, Örebro, Sweden(Swepub:oru)bua (author)
  • Lenhoff, StigLund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital, Sweden(Swepub:lu)med-slf (author)
  • Johansson, Jan-Erik,1946-Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden(Swepub:oru)jkjn (author)
  • Isaksson, CeciliaUmeå universitet,Institutionen för strålningsvetenskaper (author)
  • Hägglund, HansKarolinska Institutet,Uppsala universitet,Hematologi,University of Uppsala Hospital, Sweden(Swepub:uu)hanha689 (author)
  • Carlson, KristinaUppsala universitet,Hematologi,University of Uppsala Hospital, Sweden(Swepub:uu)krica965 (author)
  • Fagius, JanUppsala universitet,Neurologi,Uppsala University, Sweden; University of Uppsala Hospital, Sweden(Swepub:uu)janfagiu (author)
  • Uppsala universitetNeurologi (creator_code:org_t)

Related titles

  • In:Journal of Neurology, Neurosurgery and PsychiatryLondon, United Kingdom : BMJ Publishing Group Ltd85:10, s. 1116-11210022-30501468-330X

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view